AstraZeneca Plc, the UK’s biggest drugmaker, plans to list regular shares on the New York Stock Exchange to attract more investors in a further tilt toward the US, where it makes almost half of its revenue.
A direct listing of Astra’s ordinary shares will replace the existing American Depositary Receipts on the Nasdaq, the drugmaker said in a statement Monday. Astra will keep its London trading and UK headquarters.
The change reflects the rising importance of the US for Astra — and in turn, a relative shift away from its home country as Chief Executive Officer Pascal Soriot looks ...
